Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are important treatments for type 2 diabetes [7]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.